NCT02446301

A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers

A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection vs. Bain®. Nalbuphine HCl IM Injection, in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Lumosa Therapeutics Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Accepted

Summary

This study is to evaluate the relative bioavailability of nalbuphine after single IM injection of Sebacoyl Dinalbuphine Ester (SDE) injection and Bain®, Nalbuphine HCl IM injection in healthy volunteers.

Conditions

• Pain
• Analgesia Disorder

Interventions

Type	Name	Description
DRUG	Bain®	Nalbuphine HCl 20mg, IM injection
DRUG	SDE	Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2015-05-18
• Last updated: 2015-05-19

Locations

1 site across 1 country: Taiwan